LY4005130 Clinical Trials (2026): 3 Studies for Alopecia Areata & Healthy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 LY4005130 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Alopecia Areata & Healthy) and 238 total planned enrollment. 2 LY4005130 clinical trials are actively recruiting at 22 U.S. sites across 11 states. Most recent activity: NCT07533006 (Oct 2027).
Where to Participate: All LY4005130 Trial Sites in the U.S. (22 sites across 11 states)
Every actively recruiting LY4005130trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Medical Dermatology Specialists | Phoenix85006 | NCT07533019 | Map |
| CA | Center For Dermatology Clinical Research, Inc. | Fremont94538 | NCT07533006 | Map |
| CA | Center For Dermatology Clinical Research, Inc. | Fremont94538 | NCT07533019 | Map |
| CA | Northridge Clinical Trials | Northridge91325 | NCT07533006 | Map |
| CA | Northridge Clinical Trials | Northridge91325 | NCT07533019 | Map |
| CA | Cura Clinical Research - Oxnard | Oxnard93030 | NCT07533019 | Map |
| FL | Health Clinical Research, LLC | Cutler Bay33189 | NCT07533006 | Map |
| FL | Health Clinical Research, LLC | Miami33189 | NCT07533019 | Map |
| FL | K2 Medical Research - Tampa | Tampa33634 | NCT07533019 | Map |
| GA | Advanced Medical Research, PC. | Sandy Springs30328 | NCT07533019 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT07533019 | Map |
| MI | Revival Research Institute, LLC | Troy48084 | NCT07533006 | Map |
| MI | Revival Research Institute, LLC | Troy48084 | NCT07533019 | Map |
| NH | Stracskin | Portsmouth03801 | NCT07533006 | Map |
| NH | Stracskin | Portsmouth03801 | NCT07533019 | Map |
| NY | Equity Medical | The Bronx10455 | NCT07533019 | Map |
| TX | Accurate Clinical Research, Inc | Humble77346 | NCT07533019 | Map |
| TX | Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue | San Antonio78235 | NCT07533006 | Map |
| TX | Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue | San Antonio78235 | NCT07533019 | Map |
| UT | Jordan Valley Dermatology & Research Center | South Jordan84095 | NCT07533006 | Map |
| UT | Jordan Valley Dermatology & Research Center | South Jordan84095 | NCT07533019 | Map |
| VA | Clinical Research Partners, LLC | Richmond23226 | NCT07533019 | Map |
LY4005130 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1 | 1 | 1 | |
| P2 | 2 | 2 |
Recruiting LY4005130 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07533006 | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | P2 | Alopecia Areata | 60 | Apr 2026 |
| NCT07533019 | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | P2 | Vitiligo | 60 | Apr 2026 |
LY4005130 clinical trials by indication
Alopecia Areata (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07533006 | — | P2 | recruiting | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) |
Vitiligo (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07533019 | — | P2 | recruiting | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06690996 | FPAB | P1 | active not recruiting | A Study of LY4005130 in Healthy Participants |
All LY4005130 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07533006 | A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) | P2 | recruiting | 60 | Eli Lilly and Company | Apr 2026 | |
| NCT07533019 | A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo | P2 | recruiting | 60 | Eli Lilly and Company | Apr 2026 | |
| NCT06690996 | FPAB | A Study of LY4005130 in Healthy Participants | P1 | active not recruiting | 118 | Eli Lilly and Company | Nov 2024 |
LY4005130 clinical trials: frequently asked questions
- How many LY4005130 clinical trials are there?
- 3 LY4005130 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are LY4005130 clinical trials recruiting in 2026?
- Yes — 2 LY4005130 trials are actively recruiting in 2026, with 22 U.S. sites across 11 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is LY4005130 being studied for?
- LY4005130 is being studied for Alopecia Areata, Healthy, Non-Segmental Vitiligo (NSV), Vitiligo. The trials are grouped by indication on this page.
- What phase is LY4005130 in?
- LY4005130 clinical trials span 2 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors LY4005130 clinical trials?
- The lead sponsor across the most LY4005130 trials is Eli Lilly and Company. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming LY4005130as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: